Literature DB >> 35301227

Covid-19: Evusheld is approved in UK for prophylaxis in immunocompromised people.

Jacqui Wise1.   

Abstract

Entities:  

Year:  2022        PMID： 35301227     DOI： 10.1136/bmj.o722

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.

Authors:  Caroline Hirsch; Yun Soo Park; Vanessa Piechotta; Khai Li Chai; Lise J Estcourt; Ina Monsef; Susanne Salomon; Erica M Wood; Cynthia So-Osman; Zoe McQuilten; Christoph D Spinner; Jakob J Malin; Miriam Stegemann; Nicole Skoetz; Nina Kreuzberger
Journal:  Cochrane Database Syst Rev       Date:  2022-06-17

2.  Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.

Authors:  Huan Ma; Xinghai Zhang; Peiyi Zheng; Peter H Dube; Weihong Zeng; Shaohong Chen; Qingyu Cheng; Yunru Yang; Yan Wu; Junhui Zhou; Xiaowen Hu; Yan Xiang; Huajun Zhang; Sandra Chiu; Tengchuan Jin
Journal:  Cell Res       Date:  2022-07-29       Impact factor: 46.297

3.  COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events.

Authors:  William E Fitzsimmons
Journal:  Hum Vaccin Immunother       Date:  2022-05-05       Impact factor: 4.526

Review 4.  A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.

Authors:  Monika Kumari; Ruei-Min Lu; Mu-Chun Li; Jhih-Liang Huang; Fu-Fei Hsu; Shih-Han Ko; Feng-Yi Ke; Shih-Chieh Su; Kang-Hao Liang; Joyce Pei-Yi Yuan; Hsiao-Ling Chiang; Cheng-Pu Sun; I-Jung Lee; Wen-Shan Li; Hsing-Pang Hsieh; Mi-Hua Tao; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2022-09-12       Impact factor: 12.771
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.